ImmunoPrecise Antibodies Ltd.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
45257F200
SEDOL
N/A
CIK
0001715925
www.ipatherapeutics.com
LEI:
FIGI: BBG000CR68W7
IPA
ImmunoPrecise Antibodies Ltd.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
AI
PROFILER
NAME
ImmunoPrecise Antibodies Ltd.
ISIN
CA45257F2008
TICKER
IPA
MIC
XNAS
REUTERS
IPA.OQ
BLOOMBERG
IPA US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Thu, 19.12.2024       ImmunoPrecise Antibodies
CA45257F2008

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlan...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Tue, 10.12.2024       ImmunoPrecise Antibodies
CA45257F2008

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the second quarter (“Q2”) of its 2025 fiscal year (“FY25”), which ended October 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "This quarter mark...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.12.2024       ImmunoPrecise Antibodies
CA45257F2008

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced it will be presenting at The Benchmark Company’s 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024, at the New York Athletic Club in New York City. T...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Tue, 03.12.2024       ImmunoPrecise Antibodies
CA45257F2008

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday, December 10, 2024, at 10:30 am Eastern Time. Th...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Wed, 13.11.2024       ImmunoPrecise Antibodies
CA45257F2008

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery and AI capabilities, but it also strategically places the company in the rap...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       ImmunoPrecise Antibodies
CA45257F2008

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA’s latest advancements in AI-dr...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       ImmunoPrecise Antibodies
CA45257F2008

ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published in bioRxiv and subsequently peer-reviewed and published in the prestigio...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Mon, 21.10.2024       ImmunoPrecise Antibodies
CA45257F2008

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA’s AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Se...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.10.2024       ImmunoPrecise Antibodies
CA45257F2008

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Goo...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
Wed, 02.10.2024       ImmunoPrecise Antibodies
CA45257F2008

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, and Biotheus Inc. (Biotheus), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, jointly announce that the two parties have entered into a M...
Read More
ImmunoPrecise Antibodies
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S